Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: TMZ-BioShuttle – a reformulated Temozolomide. | Int. J. Med. Sci. 2008 5 273 International Journal of Medical Sciences ISSN 1449-1907 2008 5 5 273-284 Ivyspring International Publisher. All rights reserved Research Paper TMZ-BioShuttle - a reformulated Temozolomide Waldemar Waldeck1 Manfred Wiessler2 Volker Ehemann3 Ruediger Pipkorn4 Herbert Spring5 Juergen Debus6 Bernd Didinger6 Gabriele Mueller1 Joerg Langowski1 Klaus Braun2 H 1. German Cancer Research Center Division of Biophysics of Macromolecules INF 580 D-69120 Heidelberg Germany 2. German Cancer Research Center Dept. of Molecular Toxicology INF 280 D-69120 Heidelberg Germany 3. University of Heidelberg Institute of Pathology INF 220 D-69120 Heidelberg Germany 4. German Cancer Research Center Central Peptide Synthesis Unit INF 580 D-69120 Heidelberg Germany 5. German Cancer Research Center Dept. of Structural Analysis of Gene Structure and Function INF 280 D-69120 Heidelberg Germany 6. University of Heidelberg Dept. of Radiation Oncology INF 400 D-69120 Heidelberg Germany H Correspondence to Dr. Klaus Braun German Cancer Research Center DKFZ Dept. Molecular Toxicology Im Neuenheimer Feld 280 D-69120 Heidelberg Germany. Phone 49 6221-42 2495 Fax 49 6221-42 3375 e-mail Received Accepted Published There is a large number of effective cytotoxic drugs whose side effect profile efficacy and long-term use in man are well understood and documented over decades of use in clinical routine . in the treatment of recurrent glioblastoma multiforme GBM and the hormone-refractory prostate cancer HRPC . Both cancers are insensitive against most chemotherapeutic interventions they have low response rates and poor prognoses. Some cytotoxic agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic temozolomide TMZ as an .
